Press Releases

Nymox’s New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

August 29, 2016:

Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers…


Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

August 24, 2016:

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.


Nymox Announces Private Placements of $2.24 Million

August 17, 2016:

Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.


Nymox Announces Prostate Drug Progress

August 11, 2016:

Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Companys Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.


Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

June 22, 2016:

Nymox Pharmaceutical Corporation announced today results from the Companys 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Companys lead drug fexapotide.


Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study

February 9, 2016:

Nymox Pharmaceutical Corporation today announced results from the completion of the Companys U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).


Nymox Announces Additional $2.1 Million Equity Financing

February 4, 2016:

Nymox Pharmaceutical Corporation announced today private placement equity investment of US$2.1 Million.


Nymox Files Current Financial Statements

December 31, 2015:

Nymox Pharmaceutical Corporation is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements.


Nymox Provides Update From Shareholders Annual General Meeting December 16

December 17, 2015:

Nymox Pharmaceutical Corporation is pleased to report an update on the Corporations business as of December 16, 2015.


Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer

October 29, 2015:

Nymox Pharmaceutical Corporation reported today that long-term randomized cross-over data from the Companys trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.